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Glycosylation is estimated to be found in over 50% of human proteins. Aberrant protein glycosylation and alteration of
glycans are closely related to many diseases. More than half of the cancer biomarkers are glycosylated-proteins,
and specific glycoforms of glycosylated-proteins may serve as biomarkers for either the early detection of disease
or the evaluation of therapeutic efficacy for treatment of diseases. Glycoproteomics, therefore, becomes an
emerging field that can make unique contributions to the discovery of biomarkers of cancers. The recent advances
in mass spectrometry (MS)-based glycoproteomics, which can analyze thousands of glycosylated-proteins in a
single experiment, have shown great promise for this purpose. Herein, we described the MS-based strategies that are
available for glycoproteomics, and discussed the sensitivity and high throughput in both qualitative and quantitative
manners. The discovery of glycosylated-proteins as biomarkers in some representative diseases by employing
glycoproteomics was also summarized.
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Proteomics, aiming at the large-scale protein analysis in
biological samples, is useful for monitoring proteins that
are involved in physiological changes in cells or organisms
[1]. In the past two decades, proteomics has contributed
tremendously to the discovery of biomarkers in a variety
of diseases [2-5]. Although proteins perform a vast array
of biological functions in living organisms, posttransla-
tional modifications (PTMs) that are introduced after
translation further extended the range of functions of the
protein [3]. Glycosylation, one of the most common and
functionally important PTMs in mammalian cells, plays a
central role in many biological processes, including pro-
tein folding, host-pathogen interaction, immune response,
and inflammation [4]. The most common types of protein
glycosylations occur with the addition of specific glycan
residues to asparagine (N-linked glycosylation). Alter-
ations in either level or site of glycosylation can influence
the cellular processes such as growth, differentiation, me-
tastasis, and immune surveillance of tumors. Also, it is re-
ported that modifications of the glycan structures are* Correspondence: luhaojie@fudan.edu.cn
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unless otherwise stated.associated with several diseases as well. Since glycosylated-
proteins have been discovered to be the clinical biomarkers
for many diseases, for example, Her2/neu in breast cancer,
prostate-specific antigen (PSA) in prostate cancer, CA125
in ovarian cancer, and carcinoembryonic antigen (CEA) in
colorectal, bladder, breast, pancreatic and lung cancers,
glycoproteomics, as a significant branch of proteomics,
has become an emerging field for biomarker discovery
[5,6]. In a long time, proteomics and glycomics are two
separate disciplines with the proteomics studying the
whole proteome (the protein), while the glycomics focus-
ing on the glycome (the glycan). However, neither of them
can provide complete information during the progression
of diseases [7]. For instance, in some cases only the
concentration of glycosylated-protein, the glycosyla-
tion occupancy on a certain site, or the structure of the
oligosaccharide changed, while in most of the others,
all three factors may vary at the same time. Therefore,
it is necessary to have an inter-discipline of glycoproteo-
mics that can not only qualify and quantify the proteins as
the traditional proteomics, but also take the following two
more aspects into account: 1) protein glycosylation sites
(the occupancy extent of glycosylation sites); and 2) glyco-
sylation forms (the alterations from the attached glycan
compositions and structures). Glycoproteomics, as aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the profile of glycosylated proteins from both protein
and glycan parts, would make unique contributions to
the discovery of biomarkers of cancers.
Typically, there are several goals to be achieved in the
development of potential biomarkers by glycoproteomics:
1) to identify the glycosylated-proteins, their glycosylation
sites, and the glycan compositions; 2) to quantify the
glycosylated-proteins and their glycosylation extent; 3) to
validate the potential glycosylated-protein biomarkers; and
4) to establish the clinical test method. Complete glyco-
proteome analysis requires multiple methods, due to the
complex linkage of the glycan to the protein and the var-
iety of glycan compositions. In recent years, considerable
works have been done to characterize the sequences of
the glycosylated-proteins, the primary structures of the
glycan attached to proteins, and the related glycosylation
site occupancy. Mass Spectrometry analysis in combin-
ation with modern separation methodologies is one of the
most powerful and versatile techniques used to studyFigure 1 Strategy of the mass spectrometry-based N-glycoproteome.glycoproteome, because of its strong capabilities of pro-
viding both qualitative and quantitative information
[8,9]. In general, N-glycoproteomics methodology con-
sists of isolation and/or enrichment of glycosylated-
proteins, proteolytic digestion, and detection of peptides
for protein characterization and glycosylated-peptides
for glycan composition analysis using MS (Figure 1). In
N-linked glycosylated-proteins identification, the glycan
are usually detached from the glycosylated-proteins/gly-
cosylated-peptides using enzyme such as PNGase F [10].
Information of glycan composition, sequence, branching,
glycosylation site, and relative quantification can thus all
be obtained using MS-based methods. The conventional
proteomics strategies have enabled enormous advances in
the field during the past decade; however, they are still fa-
cing a bioanalytical challenge with the complex structure
of glycans, which requires multiple MS-based approaches
to gain different types of information.
In this review, we have summarized the current existing
MS-based technologies that are utilized for characterization
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the understanding of glycosylated-proteins as biomarkers
of some representative diseases.
Characterization of glycosylated-proteins by mass
spectrometry
Glycosylated-proteins/ glycosylated-peptides enrichment
A complete characterization of glycosylated-protein in-
cludes identification, glycosylated site location, glycan
structure elucidation and the functional study of the
glycosylated-proteins. However, the glycoproteome is
overshadowed by the complicated cellular environment,
the relatively low abundance (2% to 5%) and low
ionization efficiency of glycosylated-peptides. Therefore,
the effective separation of glycosylated-proteins/glyco-
sylated-peptides combined with appropriate mass spec-
trometry fragmentation mode would facilitate more
desirable identification result [1,11]. Generally speaking,
the common enrichment method can be divided into af-
finity approach and chemical approach. The former is
based on the interaction of sugar chains and stationary
phase such as lectin affinity chromatography, titanium
dioxide affinity chromatography and hydrophilic interactionFigure 2 The common enrichment strategies for N-glycoprotein/glycoliquid chromatography, while the latter realize immobilization
of glycosylated-protein/glycosylated-peptide relying on the
chemical reaction of glycans and specific functional group,
such as hydrazide chemistry, reductive amination chemis-
try and boronic acid chemistry shown in Figure 2.
Lectin affinity chromatography
In the last decades, carbohydrate-binding proteins, known
as lectins, have been widely exploited for the isolation of
glycosylated-proteins or glycosylated-peptides from com-
plex samples. Lectin has the capability to bind to distinct
oligosaccharide epitopes. As early as 1970, Aspberg and
Lloyd first applied lectin affinity for enrichment of
glycosylated-proteins [12,13]. Since then, numerous re-
search using lectins to enrich glycosylated-proteins/glyco-
sylated-peptides have been developed. According to a
fresh review, at least 160 lectins are known to researchers.
Among them, more than 60 kinds are commercially avail-
able [14]. One kind of lectins includes concanavalin A
(Con A) [15], wheat germ agglutinin (WGA) [16] and
jacalin (JAC) [17], etc. They are all known to have broad
specificity and can react with many different glycosylated-
proteins. While, the more specific lectins, such as Sambucuspeptide.
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tached to terminal galactose in α-2,6 linkage, are often ap-
plied to adsorb a definite subset of the glycoproteome
[14]. Therefore, the lectin method not only can target a
broad type of glycans (e.g. Con A is often used for binding
high-Man N-linked glycans) but also is appropriate for
enrichment of glycans containing specific structures
(e.g. L-phytohemagglutinin, or L-PHA, will recognize
β (1,6)-branched N-linked glycans [18]) Lectin affinity
chromatography based glycosylated-proteins/glycosyl-
ated-peptides enrichment strategy followed by down-
stream proteomic analysis has been successfully applied
to variety kinds of biological samples, most frequently,
in blood [19-23].
In the recent study of serum biomarker, Jung et al. took
the advantage of narrow specificity lectins, which target
more specific features of glycosylated-proteins to study
disease associated aberrations in glycosylation [24]. They
observed that approximately 30% of the plasma secretome
can be captured using Con A alone, which has broad re-
activity for the mannose cores typically found in N-linked
glycans. Two fucose-specific lectins, Aleuria aurantia lec-
tin (AAL) and Lens culinaris agglutinin (LCA), were found
to bind 4% and 8% of the total plasma proteins, res-
pectively. Highly specific Wisteria floribunda agglutinin
(WFA)-assisted glycoproteomics approach was developed
adopting dual enrichment. The combination of dissection
of the WFA-stained cholangiocarcinoma tissue region and
WFA-agarose column chromatography successfully iden-
tified 71 proteins as candidate markers with the assistance
of subsequent analysis by mass spectrometry [23]. The
limitation of enrichment approaches based on lectin is
that no single lectin has the ability to bind the whole
glycoproteome. Due to maximizing capture of majority of
glycosylated-proteins in one step, enhanced binding
strengths were often acquired by multi-lectin affinity
chromatography. Kullolli et al. recently developed a
High Performance Multi-Lectin Affinity Chromatography
(HP-MLAC) composed of lectins ConA, JAC, and WGA.
The effective integration of protein depletion, glycosylated-
proteins enrichment and in-line sample concentration/
desalting allowed the minimization of sample loss and
the improvement of the depth of the plasma proteome
analysis [25].
Titanium dioxide affinity chromatography
Titanium dioxide (TiO2) was often used to capture
phosphopeptides from the complex sample. Larsen et al.
presented a simple but highly selective strategy for en-
richment of sialic acid-containing glycosylated-peptides
[26]. The negatively charged sialic acid, which contains
both carboxylic acid and hydroxyl group may interacts
with TiO2 molecules via a multipoint binding. There-
fore, after dephosphorylation by alkaline phosphatase,interaction will specifically occur between TiO2 and sialic
acid. Under specific buffer conditions, nonglycosylated-
peptides or neutral glycosylated-peptides were no longer
bound onto the TiO2. A total of 192 and 97 sialic acid-
containing glycosylation sites from depleted human
plasma and saliva were identified, respectively in this way
[26]. Zhao et al. made a profound profiling of the sialy-
lated N-glycoproteomics in human plasma by an opti-
mized strategy of combination of a filter-aided sample
preparation, TiO2 chromatography enrichment, multiple
enzyme digestion, and high-pH reversed-phase peptide
separation. 982 glycosylation sites in 413 proteins were
identified, providing the largest database in human plasma
until now [27]. Considering that TiO2 displays high speci-
ficity to enrich the phosphopeptides, it can be utilized for
comprehensive studies of both types of two PTMs simul-
taneously in one enrichment procedure [28].
Hydrophilic interaction liquid chromatography (HILIC)
Although hydrophilic interaction liquid chromatography
(HILIC) was first introduced as early as 1970s to analyze
saccharides [29], recent years have seen its versatile ap-
plication for the separation of biomolecules. Relative to
reversed phase liquid chromatography (RPLC), HILIC is
featured by the use of a hydrophilic materials as station-
ary phase and a hydrophobic organic solvent as mobile
phase, which can be regarded as a kind of normal-phase
(NP) chromatography. HILIC makes it viable for the
multidimensional separation of complex samples in prote-
omics applications, especially analysis of post-translational
modifications. Yet, NP is often performed with non-
water-miscible solvent buffers but the mobile phase used
by HILIC is similar to those employed in the RP-LC mode.
Therefore, HILIC has specific advantages such as less
complicated eluent preparation, good solubility of polar
samples and greater compatibility with electrospray MS.
Richness of hydroxyls makes glycosylated-peptides more
hydrophilic, which means that HILIC is suitable for
glycosylated-peptide separation. Analytes and polar sta-
tionary phase are interacted with each other in the form
of hydrogen bonding. However, the deep mechanism of
HILIC is different because of various stationary phases.
Classical HILIC stationary phases were made of bare
silica or silica gels modified with polar functional groups.
For example, polyhydroxyethyl aspartamide column was
used to help the enrichment of glycosylated-peptides
from depleted plasma prior to MS analysis. Interestingly,
the author demonstrated that TFA as an ion-pairing re-
agent could improve enrichment efficiency [30]. The
idea of employing carbohydrate materials as modifi-
cation of HILIC was based on hydrophilic binding principle
of carbohydrate matrices such as cellulose and sepharose to
oligosaccharides [31]. IgG isotype-specific Fc glycosylation
profiles were characterized relying on HILIC-SPE with
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pointed out sepharose-SPE displayed allowed a faster and
more constant flow due to more homogeneous particle
sizes [32]. Cotton wool, recently, was creatively introduced
into HILIC SPE microtips to remove salts, most non-
glycosylated peptides, and detergents. Purification of
N-glycans after PNGase F deglycosylation treatment of
IgG and transferrin was also obtained by cotton HILIC
microtips [33].
Huang et al. put forward a new material bonded on
HILIC silica with the help of diazotransfer reagent to
transfer the partial amino groups in chitooligosaccharides
to azido groups [34]. Compared to Sepharose, click-
maltose on silica beads is more flexible, producing ad-
equate hydroxyl groups to capture glycosylated-peptides
and improving selectivity [35]. An automatical sample
pretreatment workflow, composed of a click maltose-
HILIC column for glycosylated-peptide enrichment, a
strong cation exchange (SCX) precolumn for sample buf-
fer exchange, and a PNGase F immobilized enzymatic re-
actor (IMER) for online deglycosylation was established,
allowing improved sensitivity (detection limit of 5 fmol
glycosylated-peptide) and selectivity (interfering 50 times
(mass ratio) of BSA) [36].
The application of HILIC with zwitterionic materials is
developing rapidly in the glycoproteomics. A charged li-
quid layer is generated near the stationary phase surface,
creating a region of high ionic strength for polar interac-
tions with glycan. The electrostatic interactions between
the two oppositely charged groups is almost at a stoi-
chiometric ratio, which is relatively weaker when com-
pared to normal ionic exchangers such as SCX [37]. A
two-dimensional chromatographic protocol with a com-
bination of off-line ZIC-HILIC and RP chromatography
including column packing, LC setup and gradient
optimization was described. The strategy made it pos-
sible to improve sensitivity and handle small sample vol-
umes, compatible with the stable isotopic label methods
for quantitation used in glycoproteomics [38]. However,
it is worthwhile to note that the selectivity of HILIC is
relatively low as the coseparation of hydrophilic non-
glycosylated-peptides.
Hydrazide chemistry
A solid-phase extraction method to enrich glycosylated-
proteins based on hydrazide chemistry was first devel-
oped by Zhang et al. [39]. The methodology includes
four steps: 1) Periodate oxidation of carbohydrate cis-
diol groups to aldehydes. 2) Hydrazone formation be-
tween aldehydes and hydrazide groups on the support
medium. 3) Tryptic digestion of the immobilized pro-
teins in order to remove the nonglycosylated peptides. 4)
Liberation of glycosylated-peptides from the support
with PNGase F. Attributed to the good specificity andnice sensitivity of hydrazide chemistry-based enrichment
approach, many kinds of complex biological samples
have been investigated under this method. However, the
glycan moiety was destroyed so the analysis of the struc-
ture of glycan was difficult. In order to make this isolation
of glycosylated-protein/glycosylated-peptide easier, mag-
netic particles modified with hydrazide group may be syn-
thesized [40-42]. Due to the enormous complexity of real
biological samples, hydrazide chemistry combined with
other pretreatment protocols will further increase the sen-
sitivity and coverage of detection. For example, some pre-
treatments such as the depletion of high-abundant protein
or separations by two-dimensional chromatographic will
increase the sensitivity of the method [41]. Furthermore,
increased glycosylated-protein sequence coverage was
proved by a two-step protease digestion (Lys-C digestion,
hydrazide resin separation, trypsin digetstion and PNGase
F deglycosylation) [43]. Multiple enzyme digestion (tryp-
sin, pepsin and thermolysin) significantly improved the
coverage of N-glycosites [44]. In addition, Parker et al.
adopted parallel enrichments strategy to reveal a deeper
analysis of glycoproteome, with a total of 1556 nonredun-
dant N-linked glycosylation sites from 972 protein groups
identifications [45]. Compared with lectin method, hydra-
zide chemistry-based enrichment turned out to be more
specific due to its covalent bonding to the carbohydrates.
Reductive amination chemistry
Recently, our group improved the traditional hydrazide
chemistry by introducing reductive amination to enrich
N-Linked glycosylated-peptides for the first time. The
enrichment strategy is based on the reaction between al-
dehyde groups which were produced by oxidation of the
cis-diol groups of glycans and amino groups modified
on the magnetic nanoparticles. Compared to the hydra-
zide chemistry-based solid phase extraction, this proto-
col eliminated the desalting step and shortened the
extraction time to 4 h, improving the detection limit of
glycosylated-peptides by 2 orders of magnitude. A total
of 111 N-glycosylation sites were identified in 108
glycosylated-peptides in only 5 μL of human serum [46].
Boronic acid chemistry
Boronate esters are selectively formed under alkaline
condition and the reversed-reaction can occur under
acidic conditions [47]. Therefore, boronic acid chemistry
can be utilized for the capture and release of cis-diol-
containing molecules such as glycans. The reversible, co-
valent bonds between boronic group and vicinal diols of
glycans endow boronic acid “lectin-like” properties.
However, the recognition between the glycosylated-
peptide and boronic acid does not need a complicated
discrimination motif, which means that boronic acid
have a more broad binding ability to glycans than lectin
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capture/liberation of glycoconjugates, which make bo-
ronic acid-based enrichment for glycosylated-proteins/
glycosylated-peptides attractive.
Our group took advantage of FDU-12 which showed
good selectivity towards glycosylated-peptides to dramat-
ically enhance the LOD of glycosylated-peptides by close
to 2 orders of magnitude [48]. We further made use of
mesoporous silica MCM-41 to be functionalized with bo-
ronic acid groups. The boronic acid-functionalized MCM-
41 silica was demonstrated to have excellent selectivity
(glycosylated-peptides/nonglycosylated-peptides at molar
ratio of 1:100), good binding capacity (40 mg g−1) and high
recovery of glycosylated-peptides (88.10%) and was ap-
plied to reveal rat serum glycopeptidome for the first time,
identifying 15 unique glycosylation sites originating from
15 different endogenous glycosylated-peptides [49].
Mass spectrometry analysis
Mass spectrometry is by far the most powerful analytical
technique which allow the qualitative and quantitative
analysis of glycosylated-proteins. Among the “modern”
ionization methods, two methodologically distinct ap-
proaches to investigate the structures of glycoconjugates
in complex biological sample with increasing effective-
ness and measurement sensitivity are Matrix-Assisted
Laser Desorption/Ionization (MALDI) and Electrospray
Ionization (ESI). The heterogeneous characteristic of
glycosylated-peptide complicates the corresponding MS
analysis and therefore promotes different ionization ex-
perimental conditions for different samples. For example,
neutral and basic glycosylated-peptides may be analyzed
under positively charged ions mode, while acidic glyco-
conjugates (sialic acid and sulfate containing) tend to be
detected more effectively as negatively charged [50].
A complete characterization of the structure of
glycosylated-peptides should include not only determin-
ation of the peptide’s amino acid sequence, but also the
confirmation the glycans and the site of glycosylation. The
structure elucidation mainly relies on tandem MS analysis,
through which important piece of data from the overall
the glycosylated-peptide may be obtained. Therefore, an
appropriate fragmentation method or a combination of
multiple techniques is really necessary for a comprehen-
sive analysis, which include both the information of glycan
structure and glycosylation site. Collision-induced dissoci-
ation (CID) is one of the most widely applied fragmenta-
tion mode in which molecules are usually bombarded
with an inert buffer gas to increase their internal vibra-
tional energy and fragmentation occurs when enough
energy is applied on the molecule. Therefore, in most
cases, CID is not suitable for structural characterization
because the obtained tandem mass spectrum is domi-
nated by the glycans cleavages fragments. In order togenerate maximum oxonium ion abundance and mini-
mum peptide backbone fragmentation, Roepstorff et al.
optimized the collision energies and realize more sensi-
tive and selective glycopeptides identification [51].
A complementary fragmentation mode was electron-
based methods, including electron-capture dissociation
(ECD) and electron-transfer dissociation (ETD). Com-
pared to CID, electron-based fragmentation pathways are
prior to break the peptide bonds than glycans bonds,
therefore more suitable for providing the reliable struc-
tural information about the glycosylation site because the
modifications still remain onto the peptides. In ECD, low-
energy electrons (<0.2 eV) were applied on multiply pro-
tonated peptide lead to the cleavage of N–Cα bonds to
generate a series of c and z. fragments ions [52]. Similar to
ECD, in ETD, the electron delivery is achieved through
the singly charged anions (e.g., fluoranthene anions) to the
multiply protonated peptides. The reactions can occur in
ion traps, which are less expensive than the Fourier trans-
form ion cyclotron resonance (FT-ICR) mass, in which
ECD is performed. Both ECD and ETD results preferen-
tially in c and z fragments ions. Therefore, ECD and ETD
are two excellent tools for post translational modifications
such as glycosylation and phosphorylation because the la-
bile modifications still remain onto the peptide and are
largely unaffected by the fragmentation process [53].
When used in combination with CID, the glycosylated-
peptides may be characterized to the fullest. Four model
glycosylated-proteins were used to evaluate the power of
ETD in conjunction with CID in the characterization of
tryptic glycosylated-peptides. Results showed that ETD
have the ability to provide reliable structural information
about the glycosylation site and when it was used in tan-
dem with CID, and both the glycan structure and the
amino acid sequence of the glycosylated-peptide could
be deduced [54]. A systematic approach including en-
richment, deglycosylation, mass spectrometric analysis
with CID and ETD was established for the study of
serum of hepatocellular carcinoma (HCC). By the com-
parison of matched spectra of glycopeptides with and
without fucosyl residue, ETD can help to localize core
fucosylation sites. The combination of the CID and
ETD increased the coverage and confidence of fucosyla-
tion identification [55].
By coupling an linear ion trap (LTQ) to an orbitrap
analyzer, the new type of mass spectrometer boasts sig-
nificantly higher resolution much more improved mass
accuracies than ordinary ion-trap [56]. Olsen et al. rea-
soned that the C-trap, which is originally used to store
ions could be used as a collision chamber for fragmenta-
tion at higher energies [57]. This higher-energy colli-
sional dissociation (HCD) was first used to characterize
protein glycosylation by Segu et al. [58]. Distinct Y1 ions
(peptide + GlcNAc) generated from HCD mode allowed
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Furthermore, fragment ions produced by HCD were de-
tected in the orbitrap, overcoming 1/3 cut-off limitation.
Therefore, the glycan oxonium ions can also be detected.
Scott et al. enriched Campylobacter jejuni glycosylated-
peptides by using ZIC-HILIC followed by CID/HCD as
well as CID/ETD. Based on their respective advantages,
CID/HCD allowed the identification of glycan structure
and peptide amino acid sequence, while CID/ETD en-
abled the elucidation of glycosylation. 130 glycosylated-
peptides and 75 glycosylation sites were identified
among which CID/HCD provided the majority of the re-
sults (73 sites) [59]. Ye et al. adopted HCD as the sup-
plemental dissociation technique for CID and ETD,
which can generate complementary fragments for
structural elucidation of the glycosylated-peptides. Five
glycosylated-peptides were analyzed with 23 glycoforms
identification and 100% protein sequence coverage
[60]. In a word, despite the dissociation behaviors of
glycosylated-peptide ions are complex, the diversity of
dissociation pathways can be regarded as an opportun-
ity to help us fully understand glycosylated-peptide
fragmentation processes and lay foundation of glycosylated-
peptide profiling [61,62].
Quantification
The high-throughput and accurate quantification of pro-
teins is another essential component of proteomics strat-
egies for studying cellular functions and processes. The
progresses in quantitative proteomics have provided im-
portant insights into many biological processes and inFigure 3 The common quantitative aim and related strategies for N-g
Changes in site specific glycosylation level; ② Changes in protein expressio
is depicted by a filled red circle. (b) Specific quantitative strategies for diffediscovering proteins as biomarkers. A number of robust
and accurate MS-based quantitative methods have been
developed for quantification of protein expression levels
in large scale. Besides monitoring changes in protein ex-
pression levels as the traditional quantitative proteomics,
quantitative glycoproteomic analysis should also deter-
min the both the site specific glycosylation level and the
glycosylation occupancy level. As shown in Figure 3 (a),
a glycosylated-protein can change in three typical man-
ner (taking upregulated in glycosylation level and/or up-
regulated in protein expression level as an example), ①
Changes in glycosylation; ② Changes in protein expres-
sion level; ③ Changes in protein expression level with
simultaneous changes in glycosylation level. In the whole
proteome digests, the nonglycosylated-peptides come from
both of the glycosylated-proteins and nonglycosylated-
proteins, while the glycosylated-peptides are only from the
glycosylated-proteins. Therefore, in case ①, the abundance
of nonglycosylated-peptides keeps constant, while the
abundance of glycosylated-peptides may change signi-
ficantly; in case ②, the abundance of glycosylated-
peptides remain unchanged, while the abundance of
nonglycosylated-peptides may vary dramatically; in case
③, both the abundances of glycosylated-peptides and
nonglycosylated-peptides change. According to the dif-
ferent purposes, specific quantitative strategies can be
applied as shown in Figure 3 (b).
Different methods of quantitative glycoproteomics can
be categorized into two groups: label-based and label-free.
Label-based quantification is accomplished by calculating
the ratio of mass spectrometric intensities between thelycoproteome. (a) Interpreting alterations in glycoproteomics. ①
n level; ③ Changes in glycosylation occupancy level. Glycosylation site
rent goals. “D” denote disease sample, “C” denote control sample.
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on different mechanisms to introduce labeling tags on the
peptides or proteins, including stable isotopic or isobaric
labeling using chemical reactions (e.g. dimethylation and
iTRAQ), metabolic incorporation (e.g. SILAC) and en-
zymatic reactions (e.g.18O labeling). While label-free
quantification, which does not use a compound contain-
ing stable isotope to bind to the protein, is also a widely
used technique for quantifying relative changes in com-
plex protein samples.
Relative quantification
Alteration at the site specific glycosylation level
The determination of the site specific glycosylation level
usually combines glycosylated-proteins/glycosylated-
peptides enrichment strategy, since separation of the
glycosylated-proteins/ glycosylated-peptides from the
backgrounds can reduce the sample complexity to a
large extent. Quantification can be then performed by
comparing the glycosylated-peptides with or without
detaching glycan in different samples.
In most cases, quantifications are performed using
peptides from glycosylated-peptides after detached gly-
can. Due to the multiple glycoforms that can be attached
to the peptide backbone, glycosylated-peptides always
have a high degree of heterogeneity, which contributes
to the difficulties in glycosylated-peptides identification
as well as quantification. Meantime, attachment of the
glycans makes the mass spectrum difficult to decipher.
Therefore, detaching the glycans from glycosylated-
peptides is beneficial in the following aspects for quanti-
fication. First, when a glycosylated-peptide is identified
in mass spectra, it would produce many spectral peaks
corresponding to those different glycoforms attached to
this glycosylated-peptides; the spreading of the glycosylated-
peptide ion signal among all these glycoforms would lower
the abundance of the MS signal of each peak. After de-
tached the glycans, deglycosylated-peptides with the same
amino acid composition would display as one peak in the
mass spectra, making it easy to be elucidated.; Second, it
is known that the deglycosylation step using peptide-
N-glycosidase F (PNGase F) results in a conversion of
asparagine to aspartic acid in the peptide sequence, intro-
ducing a mass difference of 0.9840 Da. The fixed mass dif-
ference combined with N-glycosylation sequence motif is
conducive to further confirmation of the glycosylation
site.
Once the glycans are detached, different glycoforms on
the specific glycosylation sites would contribute to the
total abundance of deglycosylated-peptides, the quantita-
tive results would in fact reflect the total glycosylation
profile on a specific glycosytion. Zhang et al. first de-
scribed a method for the quantification of glycosylation
profiles using deglycosylated-peptides after detachingglycans, for which, glycosylated-proteins were bound to a
solid support using hydrazide chemistry, and labeled with
isotopically light (d0, contains no deuteriums) or heavy
(d4, contains four deuteriums) forms of succinic anhyd-
ride, followed by releasing the labeled deglycosylated-
peptides via PNGase F. d0 and d4 labeled peptides were
then sent to mass spectrometric analysis, and the relative
MS intensity ratio between the two samples reflected the
glycosylation profile. The robustness of the method has
been demonstrated by the standard glycosylated-protein
analysis, and the observed ratios were close to the ex-
pected, with the differences ranging between 0% and 29%
with a mean of 8%. The authors then successfully applied
this method in quantifying the glycoproteome of different
samples, including cell membranes and human serum
[39]. Glycosylation quantification can be completed with
the combination of various enrichment methods and la-
beling methods. In Sun’s study, a solid phase based label-
ing approach by integration of glycosylated-peptides
enrichment and stable isotope labeling on hydrazide beads
was developed, with washing, labeling, and release of the
glycosylated-peptides were all performed on the hydrazide
beads sequentially. This approach was proved to be accur-
ate and had a good linearity range with 2 orders of mag-
nitude for quantification of deglycosylated-peptides. In
addition, when comparing with dimethyl labeling conven-
tionally performed in solution, the developed approach
has better enrichment recovery (10 − 330% improvement)
and high detection sensitivity. For example, when using
only 10 μg of the four standard glycosylated-protein mix-
tures and 400 μg of bovine serum album interference as
the starting sample, 42% of the annotated glycosites could
still be quantified., higher than the convetional method of
26% [63]. Cordwell and co-workers quantified the glyco-
proteome of myocardial ischemia/reperfusion injury via
iTRAQ labeling, and validated these changes with di-
methyl labeling. The iTRAQ approach revealed 80/437
deglycosylated-peptides with altered abundance, while di-
methyl labeling confirmed 46 of these and revealed an
additional 62 significant changes. In their strategy, they
employed a series of different enrichment methods includ-
ing hydrazide capture, titanium dioxide and HILIC with
multiple proteases to increase glycoproteome coverage
[45]. Moreover, to enable the accurate and large scale
quantification of the glycosylated-protein, Mann and co-
workers developed a method combined “filter aided sa-
mple preparation” (FASP) and super-SILAC to quantify
N-glycosylated secretome during breast cancer progression
and in human blood samples. The N-glycoproteome from
the 11 cell lines that are representative of different stages
of breast cancer development were obtained by the FASP
flow and then analyzed by LC-MS/MS. Then a super-
SILAC mix was developed by collecting conditioned
medium from three representative different heavy stable
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spike-in standard when being mixed with the conditioned
medium of the tested cell lines for all samples accurate
quantification. A total of 1398 unique N-glycosylation sites
were identified and quantified, and biologically relevant
differences were clearly reflected by N-glycosylated secre-
tome profiles [64].
If the enrichment strategy is performed at the protein
level, nonglycosylated-peptides from the glycosylated-
proteins can also be used to quantify the glycosylation
profile. As glycosylations only occur on a less part of the
amino acid, it is obvious that the nonglycosylated-
peptides are dominated in the whole proteome digest. If
all of the non glycosylated-peptides are derived from
glycosylated-proteins, the nonglycosylated-peptides can
be used as the substitutes of glycosylated-peptides for
quantification the total glycosylation profile, which would
make the quantification more accurate and reliable due to
more peptides being employed. Zou et al. developed a
relative quantitative method for profiling the glycopro-
teome of human serum from hepatocellular carcinoma
patient and healthy people, using nonglycosylated-
peptides derived from glycosylated-proteins instead of
glycosylated-peptides. They first captured glycosylated-
proteins from serum samples on a solid-phase to ensure
that the nonglycosylated-proteins would not be retained
for further analysis. Therefore, all of the nonglycosylated-
peptides came from the glycosylated-proteins. Then,
nonglycosylated-peptides were released from the solid-
phase of by trypsin digestion, separated by two-dimensional
liquid chromatography, and analyzed by tandem MS. Pro-
tein quantification was achieved by a label-free quantitative
method, which compared the spectrum counts of identified
nonglycosylated-peptides between different samples. This
method was demonstrated to have almost the same specifi-
city and sensitivity in glycosylated-proteins quantification
as capture at glycosylated-peptides level. The differential
abundance of proteins present were quantified with high
confidence at the concentration as low as nanogram per
milliliter levels [65]. For the accurate and specific quantifi-
cation of the cell surface glycosylation profile, they further
proposed a modified cell surface-capturing strategy, where
the glycosylated-peptides were submitted to LC-MS/MS
analysis directly for identification of glycosylated-proteins,
and the nonglycosylated-peptides were isotopically labeled
for quantification of glycosylated-proteins. 33 glycosylated-
proteins were quantified with significant expression
change between the two cell lines of Chang Liver and
HepG2 cells [66].
While most of the quantitation methods were based on
deglycosylated-peptides, Ye and co-authors reported a
quantification method achieved by comparing glycosylated-
peptides without detaching the glycans in a recent study,
combining a comprehensive LC-MS analysis method withtandem mass tag (TMT) labeling. Because the glycans are
retained, the quantitative results are closely related to the
glycoforms, it is a glycoform specific glycosylation quanti-
tation. The glycosylated-peptides were directly qualita-
tively and quantitatively characterized on an Orbitrap
mass analyzer with data-dependent tandem mass spec-
trometry (MS/MS) by alternating collision-induced dis-
sociation (CID), electron-transfer dissociation (ETD), and
higher-energy collisional dissociation (HCD) scans. The
CID and low-energy HCD MS/MS analysis were per-
formed to generate fragment ions by cleavage of glycosidic
bonds, and these fragments were used for peptides se-
quencing and glycan structure elucidation. In addition,
isomeric glycosylated-peptides with a slightly different se-
quence of glycan moiety could also be differentiated by
CID. ETD, which tended to preserve labile PTMs, allowed
not only the identification of the amino acid sequence of a
glycosylated-peptide but also the assignment of its glyco-
sylation sites. HCD combined with a TriVersa NanoMate
that used to collect and reinfuse target glycosylated-
peptides fractions, were performed to generate reporter
ions from the tandem mass tag, and thus, provided the
quantitative information for glycosylated-peptides. By al-
ternatively using three different dissociation methods, 23
glycoforms from all 5 corresponding glycosylated-peptides
were identified from tryptic digests of bovine fetuin.
Nonglycosylated-peptides and glycosylated-peptides were
simultaneously quantified with quantification errors less
than 9% for all examined peptides and the results from
nonglycosylated-peptides and glycosylated-peptides were
comparable with % RSD less than 10 in most cases. How-
ever, because of the complexity of real sample, this
method has only been applied to the standard sample
analysis [60]. Radoslav et al. reported a LC-MS-multiple
reaction monitoring (MRM) workflow that using glyco-
sylated-peptides to quantify the glycan-specific glycosyla-
tion of Haptoglobin in liver cirrhosis and hepatocellular
carcinoma. To achieve quantification of the Hp-T3 glyco-
forms, intense oxonium ions that are easily generated in
CID of glycosylated-peptides, were selected for quanti-
fication. The glycoform-specific oxonium and peptide-
HexNAc fragments were used to assure specificity of
detection. The quantitative analysis showed that 14 multi-
ply fucosylated glycoforms increased significantly in the
liver disease group, comparing to healthy controls with an
average 5-fold increase in intensity (p < 0.05). At the same
time, 2 tri-antennary glycoforms without fucoses did not
increase in the liver disease group and 2 tetra-antennary
glycoforms without fucoses showed a marginal 40% in-
crease in intensity at most. However, the complex
glycosylated-peptide mixtures made it difficult to realize
the specificity of these transitions, therefore, this strategy
should begin with the purification of target glycosylated-
protein from patient plasma [67].
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Quantitation of the alteration at the protein level is quite
similar to the traditional quantitative proteomics analysis
and it can be performed through label-based or label-
free approaches. In these cases, enrichment strategy can
be omitted because the quantification focuses on the
total amount of proteins including their native states
and glycosylated counterparts. Glycosylation site is only
qualitative analysis by mass spectrometry to affirm the
glycosylated-protein. Because the whole procedure can
be found in traditional quantitative proteomics, we will
not discuss in detail in this review.
Alteration at the glycosylation occupancy level
Glycosylated site occupancy is defined as the percentage
of the protein that a site is occupied by glycan. So when
analyzing the alteration in the glycosylation occupancy
level, the alteration of glycosylation extent and the alter-
ation of protein should be both taken into consideration.
Because nonglycosylated-peptides can be from either
glycosylated-protein and or their glycosylated-protein
counterparts, the total nonglycosylated-peptides of a
protein reflect the level of this protein including its na-
tive state and glycosylation state. While to obtain the
glycosylation profile, glycosylated-proteins are always
first digested into peptides, among which, the glycosylated-
peptides are then selectively enriched to reflect the glycosyl-
ation profile. The glycosylation site occupancy, then, can be
calculated from the ratio between the glycosylated-peptides
and nonglycosylated-peptides (including ones that are
from non glycosylated-proteins and its glycosylated coun-
terparts). Our group has developed a tandem 18O stable
isotope labeling (TOSIL) method to quantify the changes
in glycosylated-proteins expression and the individual N-
glycosylation site occupancy. Digests of two samples for
comparison were labeled in H2
18O or H2
16O catalyzed by
trypsin to introduce a mass tag on the C-termini of pep-
tides, and the glycans were then released with PNGase F
hydrolysis in H2
18O or H2
16O respectively to introduce a
mass tag of 18O or 16O on the glycosylation site. As a re-
sult, the relative quantities of total protein level were ob-
tained by measuring the 18O/16O intensity ratios of
nonglycosylated-peptides, while the relative quantities of
glycosylated-protein level could be obtained by measuring
the intensity of deglycosylated-peptides. Therefore, N-
glycosylated site occupancy could be obtained by com-
paring the ratio of glycosylated-proteins level and total
protein level of the two samples. By employing the TOSIL
approach, it yielded a good linearity for the quantitative
response of the N-glycosylated site occupancy, which was
within a 10-fold dynamic range with a correlation coeffi-
cient r2 > 0.99. This strategy was then successfully applied
to the analysis of serum glycoproteome between ovarian
cancer patients and healthy controls, and results showedthat changes in N-glycosylation occupancy at specific sites
did not always have the same trends as those of protein
expression levels [68]. In addition, Shakey et al. developed
a similar strategy with the same labeling methods but dif-
ferent enrichment method for relative quantitation of
glycosylated-proteins site occupancy [42]. Ueda et al. re-
ported an approach termed isotopic glycosidase elution
and labeling on lectin column chromatography (IGEL) for
profiling serum biomarkers in lung cancer patient serum.
Protein digests were first labeled with 8-plex iTRAQ re-
agent, followed by the capturing of glycosylated-peptides
with lectin-column chromatography and the tagging
of the N-glycosylation sites with 18O by PNGase F.
Nonglycosylated-peptides labeled with iTRAQ were used
to quantify the glycosylated-proteins in the protein ex-
pression level, whereas deglycosylated-peptides labeled
with iTRAQ were used to quantify the glycosylation de-
gree. With the aid of a 8-plex labeling reagent, this tech-
nology allowed the comparisons of up to eight different
samples within a single experiment [69].
Absolute quantification
Quite often, the “hypothesis-generating” relative quanti-
fication experiments mentioned above are worthless for
defining the abundance of a protein. Therefore, subse-
quent experiments are strongly needed to target them
explicitly through absolute quantification. Targeted quan-
tification of proteins is a daily task in biological research,
but traditional immunoaffinity-based methods cannot
reach desired levels of sensitivity and throughput. In
conjunction with the stable isotope dilution method, MS-
based selected reaction monitoring (SRM) and MRM as-
says have opened new avenues for absolute quantification
of the target protein, with unparalleled sensitivity and
high-speed [70,71]. Domon et al. designed a heavy iso-
tope–labeled synthetic peptide with C-terminal lysine and
arginine labeled with 13C and 15 N, respectively. Especially,
the asparagine (N) at the N-X-S/T motifs was replaced
with aspartic acid (D) to mimic the deglycosylated-
peptides. Then the heavily labeled peptides were used in
the SRM workflow for absolute quantitative of the target
glycosylated-proteins. However, this protocol can only
quantify the concentration at the protein level, while the
degree of glycosylation could not be distinguished [72]. In
recent work, Ruedi et al. reported a large scale absolute
quantitative method for N-glycoprotome by SWATH-MS.
SWATH-MS is a data-independent (DIA) acquisition
mass spectrometric method in which data are acquired on
a fast, high resolution Q-TOF instrument. By repeatedly
cycling through sequential isolation windows over the
whole chromatographic elution range, SWATH generates
a complete digital archive of all possible ions in a single
analysis for permanent, retrospective, quantitative MS/MS
analysis of complex samples. It thus can thus potentially
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with those of SRM (high reproducibility and sensitivity).
The author utilized isotopically labeled heavy forms (con-
taining either a C-terminal [13C615N4] Arg or [13C615N2]
Lys residue) of deglycosylated-peptides as the “absolute
quantification” (AQUA) peptides to realize the quan-
tification. Their results showed that compared to
SRM, SWATH acquisition allowed the quantification of
plasma glycosylated-proteins with equal variances, simi-
lar accuracy, and dynamic range, except for a slightly
higher LOQ (2–3 times less sensitive) [73]. While the
above-mentioned works focused on the absolute quanti-
fication of glycosylated-proteins, Ruhaak et al. have de-
veloped a method using MRM to examine quantitative
changes in glycosylation at a site-specific level. They
first performed studies on tuning the MS conditions for
nonglycosylated-peptides and glycosylated-peptides, using
standard IgG to construct suitable transitions. Then, the
absolute concentrations of proteins were obtained using
nonglycosylated-peptides and absolute glycosylated-proteins
concentration and site-specific quantitation of individual
glycoforms were obtained using glycosylated-peptides.
Both nonglycosylated-peptides and glycosylated-peptides
were quantified using MRM in the same run. Conse-
quently, this new approach provided information regarding
both the absolute amount of protein and the site-specific
glycosylation profile, which is useful to determine if altered
glycosylation profiles in serum/plasma were due to a
change in protein glycosylation or a change in protein
concentration. This strategy also showed a low limit of de-
tection of 60 attomoles, and a wide dynamic range of 3 or-
ders magnitude for IgG protein quantitation [74].
Diseases
N-linked glycosylated-proteins, have been shown to be
increasingly important in biomarker analyses and bio-
pharmaceutical drug development [75]. Aberrant protein
glycosylation may result in abnormal changes in bio-
logical function/activity, protein folding, and molecular
recognition in cancer. The site of protein glycosylation
and the structure of the oligosaccharide could also be al-
tered during initiation or progression of disease [75,76].
Cancer has emerged as the most dreadful disease in the
world. Although there has been a great deal of progress
in treating it in the last decades, cancer still claims hun-
dreds of thousands of lives each year. The discovery of
these cancer-associated modifications of glycans on the
glycosylated-proteins may also improve on the specificity
of existing cancer biomarkers. For example, elevation of
serum alpha-fetoprotein (AFP), a common marker for
hepatocellular carcinoma (HCC), also occurs in non-
HCC conditions such as pregnancy. In contrast, AFP-L3,
consisting of core-fucosylated glycoforms of AFP, pro-
vides better specificity for HCC. The most deadly formsof cancer in the world include lung cancer, colon cancer,
breast cancer, pancreatic cancer, liver cancer et al. We
will discuss recent advances of glycoproteomics in these
common cancers in the following parts to demonstrate
the usefulness of glycoproteomics in biomarker discov-
ery, diagnosis and subtype classification et al.
Breast cancer is the most frequently diagnosed cancer,
and it is the leading cause of cancer death among fe-
males. Recent research reported by Yen et al. showed
that glycosylated-proteins could be used to distinguish
various subtypes of breast cancer, as well as to distin-
guish normal and benign breast cells from breast cancer
cells. They obtained glycosylated-protein profiles, char-
acterized these glycosylated-proteins from 14 breast cell
lines, and then sent the glycoproteome to unsupervised
hierarchical cluster analysis. Results showed that the dif-
ferential expression of glycosylated-proteins in these
breast cancer cell lines readily allows the classification of
the lines into normal, benign, malignant, basal, and lu-
minal groups [77]. Lung cancer is the leading cancer in
males. Through quantification using MS-based glycopro-
teomic approaches, Tsai and co-authors noticed that
when compared to normal donors, the fucosylated
haptoglobin (Hp) level increased significantly in serum
of each subtype of lung cancer. They also determined
the glycan structure to be an alpha 2,6-linked tri-sialylated
trian-tennary glycan, containing alpha 1,3-linked fucose
which is attached to the four-linked position of the three-
arm mannose of N-linked core pentasaccharide [78]. As
hepatocellular carcinoma (HCC) is the most common pri-
mary malignant tumor of the liver, Liu et al. developed an
integrated platform to discover the glycosylated-protein
biomarkers in early HCC. The approach they employed is
to use lectin arrays combined with LC-MS/MS-based
quantitative glycoproteomics. Lectin arrays analysis showed
an elevation of fucosylation level of serum glycosylated-
proteins from HCC compared with cirrhosis patients. Fi-
nally, C3, CE, HRG, CD14 and HGF were found to be
biomarker candidates for distinguishing early HCC from
cirrhosis, with a sensitivity of 72% and specificity of 79%
[79]. Among the newly discovered potential biomarkers in
HCC, AFP-L3 (a glycoform of alpha-fetoprotein, AFP) is
recently approved by FDA as as a supplemental test in pa-
tients with elevated total AFP. Because elevation of serum
AFP, a common marker for hepatocellular carcinoma
(HCC), also occurs in non-HCC conditions such as preg-
nancy, AFP-L3, consisting of core-fucosylated glycoforms
of AFP, provides better specificity for HCC. AFP-L3 levels
have been found to be related to progression from moder-
ately differentiated to poorly differentiated tumors, there-
fore, it may be used as an early diagnosis of HCC when
the tumor diameter is <2 cm [80]. Similarly, in order to
discover potential glycosylated-proteins biomarkers in
ovarian cancer, Wu et al. applied a lectin array and
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approach. After being labeled with isobaric chemical
tags, glycosylated-proteins were enriched by fucose-
specific lectin array. The enriched glycosylated-proteins
were then identified and quantified by LC-MS/MS, and
five glycosylated-proteins were found to be differentially
expressed in the serum of ovarian cancer patients, com-
pared to benign diseases. With the further confirmation
by lectin-ELISA and ELISA assay, corticosteroid-binding
globulin (CBG) and other four glycosylated-proteins were
identified as potential markers for differentiating ovarian
cancer from benign diseases or healthy controls. Especially,
the combination of CBG, SAP, and CA125 showed improved
performance for distinguishing stage III ovarian cancer from
benign diseases compared to CA125 alone [81]. These above
findings clearly suggest that glycosylated-protein modifica-
tions may be a useful means to identify novel markers for
detection of cancer and monitoring of cancer progression.
Conclusions
Despite intense activities in the field of biomarker re-
search, new biomarkers are still urgently needed to ac-
celerate efforts in developing new drugs and treatments
of known diseases. Though the field of glycoproteomics
is moving forward, and more glycosylated-protein bio-
markers have been discovered, there is still much work
to do, for the future glycoproteomics research. First,
since biologically significant glycosylated-proteins often
exist in low abundance, enrichment of these glycosylated-
proteins with high specificity is still worth attention.
Second, although traditional proteomics identification
strategies can provide information on novel sites of gly-
cosylation, software and bioinformatics methods still
need to be developed to improve glycan composition
and structural analysis. Third, in order to realize effect-
ive biomarker screening, it is required to accurately
quantify the glycosylation site occupancy from both
relative and absolute aspects, as well as to analyze the
relationship between the changes in glycosylation site
occupancy and protein expression. With the progress of
glycoproteomics research, we believe that the growth in
the development of methods for high-throughput glyco-
proteomics will shed new lights on the discovery of new
biomarkers.
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